Tag
An mHealth text messaging intervention significantly improves smoking cessation rates and reduces mortality among TB patients compared to usual care, supporting its implementation in TB programs.
A secondary analysis of a randomized clinical trial finds that Hatha yoga does not provide superior sleep benefits compared to general physical conditioning in women with urinary incontinence, despite the strong correlation between nocturna
A multinational randomized trial found that adding high‑dose oral rifampin (total 35 mg/kg for 8 weeks) to standard therapy did not reduce 6‑month mortality in adults with tuberculous meningitis and was associated with more drug‑induced liv
Current evidence suggests minimal impact of omega-3 supplementation on neuropathy symptoms or quality of life in adults with diabetes.
Recent trials and meta-analyses challenge assumptions about optimal initial oxygen levels for preterm resuscitation.
This clinical trial evaluated monthly grocery vouchers for improving diabetes control in food-insecure patients, finding increased self-reported fruit and vegetable intake but no significant HbA1c improvement.
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse even
This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advan
The UMC‑UPPERGI‑01 randomized trial (n=208) found laparoscopic distal gastrectomy with D2 lymphadenectomy had similar 30‑day morbidity and mortality to open surgery for clinical T4a gastric cancer, despite longer operative times and modestl
In the MARIPOSA randomized, double-blind exploratory analysis, lazertinib monotherapy showed comparable progression-free survival, response rates, overall survival (interim), and tolerability to osimertinib in treatment-naive EGFR‑mutant ad
A phase 3 randomized trial in China showed the EGFR/HER3 bispecific antibody‑drug conjugate izalontamab brengitecan produced a 54.6% objective response rate versus 27.0% with chemotherapy in heavily pretreated recurrent or metastatic nasoph
One year of durvalumab combined with BCG induction and maintenance significantly improved disease-free survival in patients with high-risk, BCG-naive non-muscle-invasive bladder cancer compared to BCG therapy alone, with a manageable safety
A phase 3 randomized trial in East Asia found oral etrasimod 2 mg superior to placebo for induction and maintenance of clinical remission in moderate–severe ulcerative colitis, with manageable safety and notable ALT elevations.
The phase 3 PRIMIS trial found cilofexor 100 mg once daily did not reduce histological fibrosis progression at 96 weeks in non‑cirrhotic primary sclerosing cholangitis; pruritus was more frequent with cilofexor.
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
This article reviews a phase 3 trial analyzing sotatercept’s efficacy and safety in newly diagnosed pulmonary arterial hypertension patients, highlighting its potential to reduce clinical worsening early in the disease course.
The SENTIX trial shows that sentinel lymph node biopsy without full pelvic lymphadenectomy is safe in early-stage cervical cancer, potentially reducing surgical morbidity without compromising oncologic outcomes.
This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
